It should be further noted that all patients treated with the C5 complement inhibitor showed pathohistologic signs of extensive vascular and glomerular TMA (two of them with additional features of concomitant collapsing FSGS), and three of them with pathohistologic features of chronic active TMA lesions. Here, C5 is linked to focal segmental glomerulosclerosis.